- Advanced search
- Immuno Portal
- Malaria Portal
|Approved drug?||Yes (FDA (2004), EMA (2005))|
|WHO Essential Medicine||WHO Model List of Essential Medicines (21st List, 2019). Access PDF version.|
|International Nonproprietary Names|
|Avastin® | rhuMAb-VEGF|
|Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Biosimilars: Bevacizumab-awwb (Mvasi®, developed by Amgen) was the first bevacizumab biosimilar to be FDA approved (September 2017). Approval covers treatment of a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
Pfizer's biosimilar (PF-06439535; bevacizumab-bvzr; trade name Zirabev®) received EMA and FDA marketing authorisations in 2019. It is indicated for specified colorectal, breast, renal, lung, and cervical cancers by the EMA, with approval for breast cancers replaced by approval for recurrent glioblastoma under the FDA authorisation.
SB8 is in development by Samsung Bioepis (Phase 3 NCT02754882).
CBT124 (Cipla BioTech; NCT02879097) is in Phase 3 development.
|GtoPdb PubChem SID||178103377|
|Search PubMed clinical trials||bevacizumab|
|Search PubMed titles||bevacizumab|
|Search PubMed titles/abstracts||bevacizumab|